Abstract: Coagulation factorⅧ (FⅧ) replacement therapy is currently the main method for the clinical treatment of hemophilia A. Since traditional FⅧ is derived from human plasma, it has such problems as potential virus contamination and high cost. Moreover, problems caused by FⅧreplacement therapy such as poor protein stability, short half-life and inhibitor production still remain unsolved. In recent years, a variety of recombinant FⅧ-modified drugs and FⅧ antibody mimetics based on the rapid development of protein engineering technology and antibody technology have been approved for marketing or for clinical trials, which aims at improving protein stability, prolonging half-life and reducing inhibitor production. This article reviews the recombinant FⅧ-modified drugs and mimetics on the market or under investigation in recent years, which provides reference for further development of new drugs.